Sangamo Therapeutics, Inc. Common Stock
SGMO Real Time Price USDRecent trades of SGMO by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by SGMO's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$20,000 Jul 20, 2022 Issue: None
-
$20,000 Apr 20, 2022 Issue: None
-
$30,000 Jan 20, 2022 Issue: None
-
$30,000 Oct 20, 2021 Issue: None
-
$27,000 Jul 21, 2021 Issue: None
-
$27,000 Jun 22, 2021 Issue: Medical/Disease Research/Clinical Labs
Estimated quarterly lobbying spending
SGMO Revenue by Segment or Geography
New patents grants
-
Patent Title: Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof Nov. 12, 2024
-
Patent Title: Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene Jul. 23, 2024
-
Patent Title: Engineering aav May. 14, 2024
-
Patent Title: Compositions for linking dna-binding domains and cleavage domains Mar. 05, 2024
-
Patent Title: Methods and compositions for the treatment of lysosomal storage diseases Feb. 13, 2024
-
Patent Title: Methods and compositions for regulation of transgene expression Jan. 02, 2024
-
Patent Title: Method for the treatment of mucopolysaccharidosis type i Jan. 02, 2024
-
Patent Title: Regulation of gene expression using engineered nucleases Dec. 19, 2023
-
Patent Title: Engineered target specific base editors Dec. 05, 2023
-
Patent Title: Engineered target specific nucleases Nov. 28, 2023
-
Patent Title: Methods and compositions for engineering immunity Oct. 24, 2023
-
Patent Title: Artificial nucleases comprising engineered cleavage half-domains Aug. 15, 2023
-
Patent Title: Separation and quantification of empty and full viral capsid particles Aug. 15, 2023
-
Patent Title: Methods and compositions for treating huntington's disease Aug. 15, 2023
-
Patent Title: Compositions and methods for producing recombinant aav Aug. 08, 2023
-
Patent Title: Delivery of target specific nucleases Jul. 04, 2023
-
Patent Title: Dna-binding proteins and uses thereof May. 30, 2023
-
Patent Title: Genetic modification of cytokine inducible sh2-containing protein (cish) gene May. 30, 2023
-
Patent Title: Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene May. 23, 2023
-
Patent Title: Targeted integration into the ppp1r12c locus May. 16, 2023
-
Patent Title: Methods and compositions for gene inactivation May. 16, 2023
-
Patent Title: Methods and compositions for regulation of transgene expression May. 02, 2023
-
Patent Title: Methods and compositions for treating hemophilia Apr. 25, 2023
-
Patent Title: Compositions for linking dna-binding domains and cleavage domains Mar. 21, 2023
-
Patent Title: Method of making and using mammalian liver cells for treating hemophilia or lysosomal storage disorder Feb. 28, 2023
-
Patent Title: Targeted disruption of t cell and/or hla receptors Nov. 29, 2022
-
Patent Title: Tau modulators and methods and compositions for delivery thereof Nov. 22, 2022
-
Patent Title: Methods and compositions for treatment of a genetic condition Nov. 08, 2022
-
Patent Title: Liver-specific constructs factor viii expression cassettes and methods of use thereof Sep. 27, 2022
-
Patent Title: Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases Sep. 13, 2022
-
Patent Title: Zinc finger protein compositions for modulation of huntingtin (htt) Aug. 23, 2022
-
Patent Title: Engineered target specific nucleases Aug. 02, 2022
-
Patent Title: Targeted disruption of the t cell receptor Jun. 07, 2022
-
Patent Title: Methods and compositions for targeted cleavage and recombination Apr. 26, 2022
-
Patent Title: Targeted disruption of the mhc cell receptor Mar. 29, 2022
-
Patent Title: Zinc finger protein compositions for modulation of huntingtin (htt) Mar. 22, 2022
-
Patent Title: T cell modifying compounds and uses thereof Feb. 01, 2022
-
Patent Title: Methods and compositions for modulating pd1 Feb. 01, 2022
-
Patent Title: Methods and compositions for the treatment of fabry disease Jan. 11, 2022
-
Patent Title: Methods and compositions for targeted single-stranded cleavage and targeted integration Oct. 19, 2021
-
Patent Title: Artifical nucleases comprising engineered cleavage half-domains Oct. 05, 2021
-
Patent Title: Htt repressors and uses thereof Sep. 21, 2021
-
Patent Title: Methods and compositions for treating huntington's disease Sep. 07, 2021
-
Patent Title: Compositions for linking dna-binding domains and cleavage domains Jun. 22, 2021
-
Patent Title: Method for the treatment of lysosomal storage diseases Jun. 22, 2021
-
Patent Title: Gene correction of scid-related genes in hematopoietic stem and progenitor cells Jun. 01, 2021
-
Patent Title: Engineered target specific nucleases Apr. 13, 2021
-
Patent Title: Methods and compositions for regulation of transgene expression Apr. 13, 2021
-
Patent Title: Methods and compositions for genome engineering Apr. 06, 2021
-
Patent Title: Modulation of liver genes Mar. 30, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to SGMO
Recent picks made for SGMO stock on CNBC
ETFs with the largest estimated holdings in SGMO
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $SGMO stock a Buy, Sell, or Hold?
- What is the price target for $SGMO stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $SGMO stock?
- Who owns the most shares of $SGMO stock?
- What funds own $SGMO stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view SGMO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.